Sermorelin held an FDA approval, but no sermorelin product is currently marketed in the US, so there is no maintained US label to consult. The observations below come from clinical studies of GHRH(1-29), the Drugs@FDA record, and the growth hormone literature.
The short answer
Sermorelin has the cleanest safety story of any peptide on this site's GH-axis pages, and it is important to be precise about why. Both Geref products are listed in Drugs@FDA as discontinued, each with a Federal Register determination that the product "was not discontinued or withdrawn for safety or effectiveness reasons" (Drugs@FDA, NDA 020443). It was pulled because it lost commercially to recombinant growth hormone (Walker, Clin Interv Aging 2006). What that record does not cover is years of use in healthy adults for body composition or aging, which is how the compound is used today and which has never been studied.
What the regulatory record says
That Federal Register determination is a specific regulatory act, not a formality. When a drug leaves the market, FDA determines whether the withdrawal was for safety or effectiveness reasons — a finding that governs whether generic versions may ever be approved. Both sermorelin applications carry the negative finding, meaning FDA concluded it was neither.
Its approved use was also narrowly bounded in a way that reflected caution rather than risk. Geref's paediatric treatment indication covered a preselected subpopulation with idiopathic GH deficiency who first responded to a Geref stimulation test, and the label instructed that children with a peak GH below 2 ng/mL "should be excluded from Geref therapy" (FDA briefing document, PCAC October 2024). The exclusion was about efficacy — no responsive pituitary, no effect — but it also meant the drug was never given to the population least likely to benefit.
What the trials observed
In nine prepubertal children with radiation-induced GH deficiency given GHRH(1-29)-NH2 at 15 µg/kg twice daily by subcutaneous injection for a year, with three-monthly clinical chemistry, haematology, lipid and thyroid monitoring, the investigators reported "no adverse changes in biochemical or hormonal analyses" and no adverse events attributable to the therapy (Ogilvy-Stuart et al., Clin Endocrinol 1997). Bone age advanced 1.1 years per chronological year during treatment — expected with growth, and the kind of parameter that requires paediatric endocrine supervision rather than a home protocol.
In 19 older adults given a closely related GHRH(1-29) analogue at 10 µg/kg nightly for 16 weeks, fasting glucose and insulin were unchanged, and insulin sensitivity actually improved in the men (Khorram et al., J Clin Endocrinol Metab 1997). That contrasts with the glucose drift documented for ghrelin-receptor agonists, and is one of the more concrete arguments for a GHRH analogue over a GHRP — though it comes from a 16-week study in 19 people, not a safety programme.
Flushing, and why it belongs to the GHRH family
The effect most characteristic of GHRH-family compounds is vasodilatory flushing. In the original human comparison of GHRH with a growth hormone releasing peptide, mild facial flushing lasting one to three minutes occurred in 16 of 18 men given GHRH(1-44)-NH2 — and in none of those given the GHRP (Bowers et al., J Clin Endocrinol Metab 1990).
Injection-site reactions are the other recurring theme of the family. They are best quantified for the long-acting GHRH analogue CJC-1295, where irritation, erythema, induration, pain or itching occurred in roughly 70% of dosed subjects in one healthy-volunteer study and in all dosed subjects in another, with severity tracking dose (FDA briefing document, PCAC December 2024). Sermorelin is a much shorter-acting molecule and those figures are not directly transferable — but local reactions to a subcutaneously injected peptide are the single most commonly reported complaint across this entire family.
Where the reassurance stops
Four limits deserve stating plainly.
The studies were short and small. One year in nine children; 16 weeks in 19 older adults. Nothing describes multi-year use in healthy adults.
Raising GH still raises GH. Anything that reliably elevates GH and IGF-1 inherits the warnings on growth hormone labels — glucose intolerance, fluid retention, intracranial hypertension, neoplasm risk. A class review of growth hormone secretagogues called explicitly for evaluation of cancer incidence and mortality with long-term use (Sigalos & Pastuszak, Sex Med Rev 2018).
The "self-limiting" argument is partial. Sermorelin's release of GH remains subject to somatostatin negative feedback, which is the basis of the claim that overdose is difficult in a way it is not with injected growth hormone (Walker 2006). That is a genuine pharmacological difference. It is not a guarantee, and it says nothing about the effects of a modestly raised IGF-1 sustained for years.
Product identity is not covered by the old approval. The safety record above belongs to a manufactured, labelled pharmaceutical. Material sold as sermorelin outside a pharmacy supply chain carries no verified identity, purity, aggregate or endotoxin data — the attributes that drive immunogenicity risk in an injected peptide.
See also sermorelin benefits and dosing education.